Surge in China’s antibody-drug conjugates development

27 September 2024

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. With a little over 100 ADC candidates in various stages of development, Chinese companies lead the Asia-Pacific (APAC) region.

As cancer remains a significant health challenge, strategic collaborations with major pharmaceutical companies are essential for advancing research and enhancing therapeutic options, positioning Chinese firms as key players in the evolving oncology landscape, says pharma analytics company GlobalData.

According to GlobalData’s Pharmaceutical Intelligence Center, of the 124 ADCs (Phase I, II and III) currently in the pipeline for oncology across Australia, China, Japan, and South Korea, China has 102 ADCs in development, accounting for 82% of the ADC pipeline in large APAC markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK